4-(2-苯氧基乙基)哌啶 | 347873-67-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-(2-苯氧基乙基)哌啶
• 英文名称: 4-(2-phenoxyethyl)piperidine
• 英文别名: 4-(2-phenoxy-ethyl)piperidine；4-(2-phenoxyethyl)-piperidine
• CAS: 347873-67-0
• 化学式: C₁₃H₁₉NO
• mdl: MFCD09879252
• 分子量: 205.3
• InChiKey: ZTDUIZMJYASLKV-UHFFFAOYSA-N

物化性质

• 沸点：
  312.0±15.0 °C(Predicted)
• 密度：
  0.984±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(2-苯氧基乙基)哌啶 在 盐酸 作用下， 以 乙醚 为溶剂， 反应 1.5h， 生成 4-(2-phenoxyethyl)-piperidine hydrochloride salt
  参考文献：
  名称：

  WO2007/89462

  摘要：

  公开号：
• 作为产物：
  描述：

  N-Boc-4-哌啶乙醇 在 咪唑 、 盐酸 、 碘 、 potassium carbonate 、 三苯基膦 作用下， 以 甲醇 、 乙醚 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成 4-(2-苯氧基乙基)哌啶
  参考文献：
  名称：

  NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF

  摘要：

  该发明涉及吡啶基烟碱乙酰胆碱受体配体，包含有效量吡啶基烟碱乙酰胆碱受体配体的组合物，以及治疗或预防某种疾病的方法，如抑郁症和尼古丁依赖症，包括向需要的动物施用有效量吡啶基烟碱乙酰胆碱受体配体。

  公开号：

  US20130184313A1

文献信息

• [EN] PHENOXYETHYL PIPERIDINE COMPOUNDS<br/>[FR] COMPOSÉS PHÉNOXYÉTHYL PIPÉRIDINE
  申请人：LILLY CO ELI

  公开号：WO2014004229A1

  公开（公告）日：2014-01-03

  The present invention provides a compound of the Formula II: Formula II wherein X is: R1 is H, -CN, or F; R2 is H or methyl; R3 is H; and R4 is H, methyl, or ethyl; or R3 and R4 joined together form a cyclopropyl ring; or a pharmaceutically acceptable salt thereof.

  本发明提供了一种化合物，其化学式为II：其中X为：R1为H，-CN或F；R2为H或甲基；R3为H；R4为H，甲基或乙基；或者R3和R4结合在一起形成一个环丙基环；或其药用盐。
• New linear or cyclic ureas
  申请人：——

  公开号：US20010009911A1

  公开（公告）日：2001-07-26

  Compound of formula (I): 1 wherein: V represents a single bond or an alkylene chain, M represents a single bond or an alkylene chain, A and E each represents nitrogen or CH, but at least one of the two groups A or E represents nitrogen, W represents a group of formula (i), (ii) or (iii): 2 wherein: X represents carbonyl, sulphonyl or sulphoxide, G 1 , G 2 and G 3 are as defined in the description, T represents a fused phenyl group or a fused pyridyl group, R 1 represents hydrogen, linear or branched (C 1 -C 6 )alkyl, aryl or aryl-(C 1 -C 6 )alkyl in which the alkyl moiety is linear or branched, R 2a and R 2b , which are the same or different, are as defined in the description, R 3 represents aryl or heteroaryl-A as defined in the description, each of which groups may optionally be substituted, Y represents aryloxy, heteroaryloxy or heteroaryl-B as defined in the description, each of which groups may optionally be substituted, its isomers, its hydrates, its solvates and addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in the treatment of diseases or pathological conditions in which endothelial dysfunction is known.

  化合物的化学式（I）如下：其中：V代表单键或烷基链，M代表单键或烷基链，A和E各代表氮或CH，但两个基团A或E中至少有一个代表氮，W代表化学式（i）、（ii）或（iii）中的一个基团：其中：X代表酰基、磺酰基或亚砜基，G1、G2和G3如描述中定义，T代表融合苯基团或融合吡啶基团，R1代表氢、线性或支链（C1-C6）烷基、芳基或芳基-(C1-C6)烷基，其中烷基基团是线性或支链的，R2a和R2b，相同或不同，如描述中定义，R3代表芳基或杂芳基-A如描述中定义，这些基团可以选择性地被取代，Y代表芳氧基、杂芳氧基或杂芳基-B如描述中定义，这些基团可以选择性地被取代，以及其异构体、水合物、溶剂合物及其与药用酸的加合物。含有该化合物的药物产品可用于治疗已知存在内皮功能障碍的疾病或病理状况。
• New linear cyclic ureas
  申请人：——

  公开号：US20030191132A1

  公开（公告）日：2003-10-09

  Compound of formula (I): 1 wherein: V represents a single bond or an alkylene chain, M represents a single bond or an alkylene chain, A and E each represents nitrogen or CH, but at least one of the two groups A or E represents nitrogen, W represents a group of formula (i), (ii) or (iii): 2 wherein: X represents carbonyl, sulphonyl or sulphoxide, G 1 , G 2 and G 3 are as defined in the description, T represents a fused phenyl group or a fused pyridyl group, R 1 represents hydrogen, linear or branched (C 1 -C 6 )alkyl, aryl or aryl-(C 1 -C 6 )alkyl in which the alkyl moiety is linear or branched, R 2a and R 2b , which are the same or different, are as defined in the description, R 3 represents aryl or heteroaryl-A as defined in the description, each of which groups may optionally be substituted, Y represents aryloxy, heteroaryloxy or heteroaryl-B as defined in the description, each of which groups may optionally be substituted, its isomers, its hydrates, its solvates and addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in the treatment of diseases or pathological conditions in which endothelial dysfunction is known.

  化合物的式子(I)：其中：V代表单键或烷基链，M代表单键或烷基链，A和E分别代表氮或CH，但至少有一个A或E代表氮，W代表式子(i)，(ii)或(iii)的基团：其中：X代表羰基，磺酰基或硫氧化物，G1、G2和G3如说明书中所定义，T代表融合苯基团或融合吡啶基团，R1代表氢、线性或支链(C1-C6)烷基、芳基或芳基-(C1-C6)烷基，其中烷基部分是线性或支链的，R2a和R2b相同或不同，如说明书中所定义，R3代表芳基或杂环芳基-A，其中每个基团都可以选择性地被取代，Y代表芳氧基、杂芳氧基或杂环芳基-B，其中每个基团都可以选择性地被取代，其异构体、水合物、溶剂化物和其与药用可接受酸的加合物。含有此化合物的药物在治疗已知存在内皮功能障碍的疾病或病理条件中有用。
• BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF
  申请人：Burstein S. Ethan

  公开号：US20070213359A1

  公开（公告）日：2007-09-13

  Disclosed herein are compounds of Formula I as defined herein, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, that modulates the activity of a ghrelin receptor. Disclosed herein are also methods of treating diseases or conditions that comprise administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I.

  本文披露了一些公式I定义的化合物，或其药学上可接受的盐，酯，酰胺或前药，该化合物调节胃饥饿素受体的活性。本文还披露了治疗疾病或病症的方法，包括向需要的受试者施用公式I的化合物的治疗有效量。
• Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound
  申请人：Ishii Takahiro

  公开号：US20100009971A1

  公开（公告）日：2010-01-14

  A novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound or its pharmaceutically acceptable salt has a potent FAAH-inhibitory activity. Further, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound of the present disclosure is also useful in the treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain.

  一种新型的吡啶基非芳香性含氮杂环-1-羧酸酯化合物或其药学上可接受的盐具有强效的FAAH抑制活性。此外，本公开的吡啶基非芳香性含氮杂环-1-羧酸酯化合物也可用于治疗尿频、尿失禁、过度活跃的膀胱和/或疼痛。